Q2 2026 GeneDx Holdings Corp Earnings Call Transcript
Key Points
- GeneDx Holdings Corp (WGS) delivered a record quarter with over 30,000 exome and genome tests, representing 32% year-over-year growth, and returned to profitability one quarter earlier than expected.
- The company saw a significant expansion in commercial genome coverage, with Carillon's new policy increasing coverage from 47% to 87% of commercial lives in a single quarter.
- Management is focused on a clear strategy to improve the average reimbursement rate (ARR), targeting the industry standard of 70% collection rate, which represents a substantial revenue opportunity from the current 32% baseline.
- The company is successfully managing product mix, with genome mix decreasing from 40% in Q1 to 32% in Q2, and reflex volume exceeding exome volume in July, which helps optimize near-term unit economics.
- GeneDx Holdings Corp (WGS) is expanding into new markets, with the general pediatrics channel showing its highest growth ever in Q2, driven by new investments and early adoption signals.
- The company fortified its balance sheet with a $50 million debt facility expansion and an equity investment from Blackstone Life Sciences, bringing pro forma liquidity to approximately $188 million.
- Gross margins improved to 70% in Q2, up from 69% in Q1, driven by wet lab efficiency gains and early progress in deploying advanced technology across the dry lab stack.
- The blended average reimbursement rate (ARR) remained flat at $3,258 per test in Q2, and the underlying outpatient genome collection rate is only 32%, down from 43% in the same period last year.
- The company's revenue growth (11% total, 17% exome/genome) continues to lag behind volume growth (32%) due to the product mix shift toward lower-priced genome tests.
- Despite coverage expansion, many claims are still denied due to overly restricted eligibility criteria and administrative barriers, with only 67% of outpatient genome volume submitted to payers with an active positive coverage policy.
- Management expects collection rates to remain roughly flat in Q3, with meaningful improvements not expected until Q4 2026 and the most significant uplift in 2027, indicating a slow path to realizing the ARR opportunity.
- Operating cash flow in Q2 was a high point for the year, with Q3 expected to see approximately $10 million in cash outflow before returning to generation in Q4, reflecting ongoing investment and payment lags.
- Whole genome production costs are nearly twice that of exome, primarily due to higher reagent costs, which are not expected to decrease until 2027, limiting near-term gross margin expansion.
- The company's strategy of accepting volume ahead of coverage has led to a decline in collection rates, reflecting an investment in market development that has yet to translate into revenue.
Good day, and thank you for standing by. Welcome to the GeneDx. Quarter 2026 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Sabrina Dunbar of Investor Relations. Please go ahead.
Thank you, operator, and thank you, everyone, for joining us today. On the call, we have Katherine Stueland, Chief Executive Officer; Kevin Feeley, Chief Financial Officer; and Mark Gardner, President. Earlier today, GeneDx released financial results for the second quarter ended June 30, 2026.
Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, updated 2026 guidance and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, August 3, and we are under no obligation to update. When discussing our results, we refer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
